Incyte Corporation
Incyte Corporation
Your view on INCY
Overview
What the company does, where it operates, and who runs it.
About Incyte Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Herve Hoppenot
- Headquarters
- 1801 Augustine Cut-Off, Wilmington, DE, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Herve Hoppenot
- Headquarters
- 1801 Augustine Cut-Off, Wilmington, DE, US
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic.
In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma.
Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer.
It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma.
The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Incyte Corporation from FRC's valuation model, read against the market price. INCY last traded at $120.27, 57.4× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Incyte Corporation. Starting points for Incyte Corporation: P/E 57.4, EPS $1.98, beta 0.78 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Incyte Corporation. Incyte Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Incyte Corporation. Trailing twelve-month EPS for Incyte Corporation stands at $1.98. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$131.90
average of 20 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy9
- Hold10
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.92 | $1.70 | $3.22 | $8.08 |
| Low estimate | $1.74 | $1.59 | $2.51 | $7.48 |
| High estimate | $2.23 | $1.81 | $4.05 | $8.72 |
| No. of analysts | 13 | 5 | 15 | 16 |
| Year-ago EPS | $1.80 | $1.81 | $6.41 | — |
| Growth | +6.8% | -6.3% | -49.8% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.56B | $1.38B | $6.05B | $6.26B |
| Low estimate | $1.53B | $1.33B | $5.95B | $6.00B |
| High estimate | $1.60B | $1.41B | $6.10B | $6.60B |
| No. of analysts | 13 | 6 | 18 | 18 |
| Year-ago revenue | $1.51B | $1.27B | $5.14B | — |
| Growth | +3.4% | +8.5% | +17.7% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Incyte Corporation. Incyte Corporation has reported as a listed company since 1993. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- AVBPArriVent BioPharma, Inc. Common StockBiotechnology$598M
- CGEMCullinan Therapeutics, Inc.Biotechnology$617M
- EXELExelixis, Inc.Biotechnology$16.9B
- GMABGenmab A/SBiotechnology$31.8B
- LEGNLegend Biotech CorporationBiotechnology$3.0B
- LGNDLigand Pharmaceuticals IncorporatedBiotechnology$6.0B
- NRIXNurix Therapeutics, Inc.Biotechnology$1.6B
- REGNRegeneron Pharmaceuticals, Inc.Biotechnology$98.5B
More Biotechnology companies
- SNBIFSanBio Company LimitedOTC$1.3B
- SNDXSyndax Pharmaceuticals, Inc.NASDAQ$822M
- SNGXSoligenix, Inc.NASDAQ$7M
- SNNAQSienna Biopharmaceuticals, Inc.OTC$3,091
- SNTISenti Biosciences, Inc.NASDAQ$4M
ETFs holding Incyte Corporation
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.03%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.03%
- VBVanguard Small-Cap ETF$76.9B in assets0.26%
- IVViShares Core SP 500 ETF$852.9B in assets0.03%
- IDNAiShares Genomics Immunology and Healthcare ETF$352M in assets3.50%
- FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.50%
- FTXHFirst Trust Nasdaq Pharmaceuticals ETF$1.2B in assets3.26%
- PBEInvesco Biotechnology & Genome ETF$438M in assets2.58%
Largest holders first, then the funds most concentrated in INCY.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Incyte Corporation, and how their positions are changing. At a $24.51B market value, institutional positions materially move Incyte Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Incyte Corporation executives and directors. Shares of Incyte Corporation have traded between $53.56 and $109.28 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Incyte Corporation. Incyte Corporation is a $24.51B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Incyte Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Incyte Corporation. Coverage tracks Incyte Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Incyte Corporation.